Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03818854Phase 2Completed

Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

Role: lead

NCT02097641Phase 2Completed

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

Role: lead

NCT01775774Phase 1Completed

Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

Role: lead

All 3 trials loaded